Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 15c, provides guidance

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.30), $0.15 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $136.27 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2024 revenue of $645-675 million, versus the consensus of $656.4 million. SG&A expenses (GAAP) $450 - $480. R&D expenses (GAAP) $215 - $240

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance